The global ophthalmic drugs market was valued at $25bn in 2018. The market was dominated by the Retinal Disorder drug submarket which held 43% of the global ophthalmic drugs market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 215-page report you will receive 83 tables and 72 figures– all unavailable elsewhere.
The 215-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global ophthalmic drugs market revenue forecasts from 2019-2029
• Global ophthalmic drugs market revenue forecasts from 2019-2029, by submarket: • Retinal Disorder Drugs • Allergic, Inflammatory & Infective Drugs • Glaucoma Drugs • Dry Eye Drugs • Other Ophthalmic Drugs
• Revenue forecasts from 2019-2028 of the leading ophthalmic drugs: • Alphagan • Avastin • Azopt • Eylea • Lucentis • Lumigan & Ganfort • Restasis • Vigamix • Xalatan/Xalacom • Other Ophthalmic Drugs
• Our report provides an overview, revenue forecast from 2019-2029 of the ophthalmic drugs segment, revenue forecast from 2019-2029 of the leading drugs, product pipeline and SWOT analysis, for these companies: • Akorn • Allergan • Bayer • Novartis • Pfizer • Regeneron • Roche • Santen Pharmaceuticals • Senju • Valeant
• Our report provides these Qualitative Analysis: • Drivers and Restraints of the Global Ophthalmic Drugs market • SWOT Analysis of selected leading companies • Porter’s Five Forces Analysis of the Global Ophthalmic Drugs Market
• Key questions answered by this report: • How is the ophthalmic drugs market evolving? • What is driving and restraining the ophthalmic drugs market? • What are the market shares of each segment of the overall ophthalmic drugs market in 2018? • How will each ophthalmic drug submarket grow over the forecast period and how much revenue will these submarkets account for in 2029? • How will the market shares for each ophthalmic drugs submarket develop from 2018- 2029? • Which individual therapies will prevail and how will these shifts be responded to? • What will be the main growth driver of the overall market from 2019-2029? • Who are the leading players in each regional market and what are their prospects over the forecast period? • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants? • How will the industry evolve during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Global Ophthalmic Drugs Market Overview 1.2 Global Ophthalmic Drugs Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Introduction to Ophthalmic Drugs 2.1. The Pharmaceutical Industry: Very Brief Overview 2.2. The Global Burden of Eye Disease 2.3. Ophthalmic Drugs: Market Segmentation 2.4 Glaucoma: the ‘Silent Thief of Sight’ 2.4.1 A Classification of Glaucoma 2.4.1.1 Primary Open-Angle Glaucoma 2.4.1.2 Acute Angle-Closure Glaucoma 2.4.1.3 Congenital Glaucoma 2.4.1.4 Secondary Glaucoma 2.4.1.5 Normal-Tension Glaucoma 2.4.1.6 Ocular Hypertension 2.4.2 Risk Factors for Glaucoma 2.4.3 Diagnosis of Glaucoma 2.4.4 Drug Treatment of Glaucoma 2.4.5 Laser Treatment and Surgery for Glaucoma 2.5 Treatment of AMD 2.6 Diabetic Retinopathy (DR) 2.6.1 Diagnosis of Diabetic Retinopathy 2.6.2 Treatment of Diabetic Retinopathy 2.7 Ocular Allergy and Allergic Conjunctivitis 2.7.1 Diagnosis of Ocular Allergy 2.7.2 Treatment of Ocular Allergy 2.8 Ocular Inflammatory Disease 2.8.1 Treatment of Ocular Inflammatory Disease 2.9 Eye Infections 2.9.1 Treatment of Eye Infections 2.10 Dry Eye Syndrome 2.10.1 Treatment of Dry Eye Syndrome 2.11 Phases of Clinical Trials
3. Ophthalmic Drugs Market, 2019-2029 3.1 Global Ophthalmic Drugs: Market Overview 3.1.1 The World Ophthalmic Drugs Market in 2018 3.2 Global Ophthalmic Drugs: Market Forecast 2019-2029 3.3. Leading Ophthalmic Drugs 3.4 Leading Companies in the Global Ophthalmic Drugs Market 3.4.1 Top 30 Ophthalmic Drug Manufacturers 3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2019-2029 3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2019-2029 3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2019-2029 3.5.3 Glaucoma Drugs Market: Sales Forecast 2019-2029 3.5.4 Dry Eye Drugs Market: Sales Forecast 2019-2029 3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2019-2029 3.6 How Will Market Shares Change to 2029? 3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2019-2029 3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers 3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drugs Manufacturers 2019-2029 4.1 Allergan: Overview 4.1.1 Allergan: Ophthalmic Product Portfolio 4.1.1.1 Restasis 4.1.1.2 Restasis: Sales Forecast 2019-2029 4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries 4.1.1.4 Lumigan and Ganfort: Sales Forecast 2019-2029 4.1.1.5 Refresh Brand Products: The Range 4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle 4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2019-2029 4.1.1.8 Acular: New Forms Receiving FDA Approvals 4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema 4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline 4.1.3 Allergan: Ophthalmic Revenue Forecast 2019-2029 4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2019-2029 4.1.4 Allergan: SWOT Analysis 4.2 Pfizer Overview 4.2.1 Pfizer: Ophthalmic Product Portfolio 4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster 4.2.1.2 Xalatan/Xalacom: Sales Forecast 2019-2029 4.2.2 Pfizer: Ophthalmic Product Pipeline 4.2.3 Pfizer: Revenue Forecast 2019-2029 4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2019-2029 4.2.4 Pfizer: SWOT Analysis 4.3 Regeneron Overview 4.3.1 Regeneron: Ophthalmic Product Portfolio 4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin? 4.3.1.2 Eylea: US Sales Forecast 2019-2029 4.3.2 Regeneron: Ophthalmic Product Pipeline 4.3.3 Regeneron: Revenue Forecast 2019-2029 4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2019-2029 4.3.4 FDA Approves Zaltrap (aflibercept) 4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements 4.3.6 Regeneron: SWOT Analysis 4.4 Akorn Overview 4.4.1 Akorn: Ophthalmic Product Portfolio 4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales 4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck 4.4.2 Akorn: Revenue Forecast 2019-2029 4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2019-2029 4.4.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers, 2019-2029 5.1 Bayer Overview 5.1.1 Bayer: Ophthalmic Product Pipeline 5.1.2 Eylea: non-US Sales Forecast 2019-2029 5.1.3 Bayer: Revenue Forecast 2019-2029 5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2019-2029 5.2 Novartis (including Alcon) Overview 5.2.1 Novartis: Ophthalmic Product Portfolio 5.2.1.1 Lucentis: Still a Leading Drug in AMD 5.2.1.2 Lucentis: Non-US Sales Forecast 2019-2029 5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval 5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2018- 2029 5.2.1.5 Vigamox: Competes with Alcon’s Moxeza 5.2.1.6 Vigamox: Sales Forecast 2019- 2029 5.2.1.7 Azopt: Marketed in Major Markets 5.2.1.8 Azopt: Sales Forecast 2019 - 2029 5.2.1.9 Jetrea: Sales Revenues Fall Short 5.2.2 Novartis: Ophthalmic Product Pipeline 5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis) 5.2.2.2 AKB-9778 (Aerpio Therapeutics) 5.2.3 Novartis: Revenue Forecast 2019 - 2029 5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2019-2029 5.2.4 Novartis: SWOT Analysis 5.3 Roche Overview 5.3.1 Roche: Ophthalmic Product Portfolio 5.3.1.1 Lucentis: US Sales Forecast 2019-2029 5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales 5.3.1.3 Avastin: Sales Forecast 2019 - 2029 5.3.2 Roche: Ophthalmic Product Pipeline 5.3.2.1 Lampalizumab (RG7417) 5.3.3 Roche: Revenue Forecast 2019-2029 5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2019-2029 5.3.4 Roche: SWOT Analysis
7. Emerging Ophthalmic Drug Manufacturers in 2018 7.1 Acucela 7.2 Aerie Pharmaceuticals 7.3 Aerpio Therapeutics: Developing AKB-9778 7.4 Alimera Sciences 7.4.1 Iluvien: Increasing Geographical Reach and Increasing Sales 7.4.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD 7.5 Amakem 7.6 Ampio Pharmaceuticals 7.7 Chengdu Kanghong Pharmaceutical 7.8 Eleven Biotherapeutics 7.9 EyeGate Pharmaceuticals 7.10 Gene Signal 7.10.1 Aganirsen: Preventing Corneal Graft Rejection 7.11 Icon Bioscience 7.12 MacuCLEAR 7.12.1 MC-1101: a Potential Therapy for Dry AMD 7.13 Neurotech 7.14 Omeros 7.15 OphthaliX (Can-Fite BioPharma) 7.16 Ophthotech 7.16.1 Fovista: Potential Game-Changer in AMD 7.16.2 Fovista: Significant Improvement on Lucentis in Phase II Trials 7.16.3 Zimura: Complement C5 Inhibitor 7.17 Otsuka Pharmaceutical 7.18 pSivida Corp. 7.19 RXi Pharmaceuticals: Will Bevasiranib Resume Development? 7.20 Shire 7.20.1 Lifitegrast (SHP606) for Dry Eye 7.20.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity 7.21 ThromboGenics 7.21.1 Jetrea (ocriplasmin) 7.21.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline 7.22 Sun Pharmaceutical Industries Ltd. (XELPROS) 8. Qualitative Analysis of the Ophthalmic Drugs Market 2019-2029 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market 8.1.1 Rivalry Among Competitors [Medium] 8.1.2 Threat of New Entrants [Low] 8.1.3 Power of Suppliers [Low] 8.1.4 Power of Buyers [Medium] 8.1.5 Threat of Substitutes [Medium]
9. Conclusions 9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market 9.2 The World Ophthalmic Drugs Market in 2019 9.2.1 Leading Ophthalmic Drugs Market Segments 9.2.2 Leading Ophthalmic Drugs 9.2.3 Leading Ophthalmic Drug Companies 9.3 World Ophthalmic Drugs Market Forecast 2019-2029 9.4 The Future of the Ophthalmic Drugs Market? 9.4.1 Increasing Revenue Concentration among Specialist Companies 9.4.2 The Rise of Generics 9.4.3 Small Companies Can Have a Big Impact 9.4.4 What Will Succeed in the Ophthalmic Drugs Market?
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Figures Figure 1.1 Global Causes of Visual Impairment (% of Cases), 2018 Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026 Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2019 Figure 2.1 Estimated Global Blindness and Visual Impairment (% of people), 2018 Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2018 Figure 2.3 Global Causes of Visual Impairment (% of Cases) Figure 2.4 Global Causes of Blindness (% of cases) Figure 2.5 Classification of Glaucoma, 2018 Figure 3.1 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019 Figure 3.2 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019 Figure 3.3 Global Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.4 Top 9 Ophthalmic Drugs: Revenues ($m), 2018 Figure 3.5 Top 9 Ophthalmic Drugs: Market Share (%), 2018 Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs: Revenues ($m), 2018 Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2018 Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.10 Glaucoma Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.11 Dry Eye Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2018 Figure 3.14 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2023 Figure 3.15 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2029 Figure 3.16 Ophthalmic Drugs Market Drivers & Restraints 2019-2029 Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2019-2029 Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2019-2029 Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2019-2029 Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.5 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2019-2029 Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), 2019-2029 Figure 4.8 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR (%), 2019-2029 Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.11 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.13 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.1 Bayer: Eylea Revenue ($m) and AGR (%), 2019- 2029 Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019- 2029 Figure 5.3 Bayer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.4 Novartis: Lucentis Revenue ($m), AGR (%), 2019- 2029 Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR (%), 2019-2029 Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR (%), 2019- 2029 Figure 5.7 Novartis: Azopt Revenue ($m) and AGR (%), 2019- 2029 Figure 5.8 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), 2019- 2029 Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.10 Roche: Lucentis Revenue ($m) and AGR (%), 2019- 2029 Figure 5.11 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2019-2029 Figure 5.12 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2018 Figure 6.2 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2018 Figure 6.3 Santen: Eylea Revenue ($m) and AGR (%), 2019-2029 Figure 6.4 Santen: Hyalein Revenue ($m) and AGR (%), 2019-2029 Figure 6.5 Santen: Cosopt Revenue ($m) and AGR (%), 2019-2029 Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR (%), 2019-2029 Figure 6.7 Santen: Diquas Revenue ($m) and AGR (%), 2019-2029 Figure 6.8 Santen: Cravit Revenue ($m) and AGR (%), 2019-2029 Figure 6.9 Santen: Alesion Revenue ($m) and AGR (%), 2019-2029 Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.11 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.13 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2019-2029 Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2019-2029 Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress Figure 8.1 Porter’s Five Force Analysis Figure 9.1 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019
Abbott Laboratories (Abbott) Abbvie Actavis Acucela Advanced Vision Research (acquired by Akorn) Aerie Pharmaceuticals Aerpio Therapeutics Akorn Pharmaceuticals Alcon (subsidiary of Novartis) Alimera Sciences Allergan Allegro Ophthalmics Altheos Amakem Ampio Pharma Asahi Glass AstraZeneca Aton Pharma (acquired by Valeant) Banyu Pharmaceutical (part of Merck) Bausch and Lomb (subsidiary of Valeant) Bayer Bayer Yakuhin (Japanese subsidiary of Bayer) BioDiem Bicycle Therapeutics Biogen Idec BioInvent International Biovail Corporation (part of Valeant) Bristol-Myers Squibb Can-Fite BioPharma Chengdu Kanghong Pharmaceutical Chiron Corportation (part of Novartis) Chugai Pharmaceutical (part of Roche) CIBA VISION (part of Novartis) Ciba-Geigy (part of Novartis) Colby Pharmaceutical Company (Colby) CoMentis Daiichi Sankyo Eleven Biotherapeutics Eli Lilly and Company (Lilly) EyeGate Pharmaceuticals Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant) Fougera Pharmaceuticals (acquired by Novartis) Gene Signal Genentech (subsidiary of Roche) Genzyme (subsidiary of Sanofi) Gilead Sciences GSK ICN Pharmaceuticals (original Valeant company) Icon Bioscience Inamed Corporation (subsidiary of Allergan) Inception Sciences, Inc. InSite Vision Inspire Pharmaceuticals (acquired by Merck) ISTA Pharmaceuticals (part of Valeant) Jerini AG Jerini Ophthalmic (part of Jerini AG) Johnson & Johnson Kestrel Ophthalmics Kyorin Pharmaceutical Kyowa Hakko Kirin LEO Pharma Lpath MacuCLEAR MacuSIGHT, Inc. MAP Pharmaceuticals (acquired by Allergan) Meda Medicis Corporation (acquired by Valeant) Merck & Co. (Merck) MerLion Pharmaceuticals MSD K.K. (part of Merck) Mylan Pharmaceuticals Mystic Pharmaceuticals Neurotech NicOx Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim) NovaBay Pharmaceuticals Novagali Pharma (acquired by Santen) Novartis Novo (subsidiary of Novo Nordisk) Novo Nordisk Oakwood Laboratories OcuSciences Omeros Onyx Pharmaceuticals OphthaliX (part-owned by Can-Fite BioPharma) Ophthotech OPKO Health Ora OSI Pharmaceuticals Othera Pharmaceuticals (acquired by Colby) Otsuka Pharmaceutical Oxford BioMedica OXiGENE Parke-Davis (subsidiary of Pfizer) PDL BioPharma Pfizer Pharmacia (acquired by Pfizer) Potentia Pharmaceuticals Premacure Procter & Gamble pSivida Quark Pharmaceuticals Reckitt Benckiser Regeneron RetroSense Therapeutics ReVision Therapeutics Roche RXi Pharmaceuticals Sandoz (part of Novartis) Sanofi Santen Pharmaceutical Co. (Santen) SARcode Bioscience Schering-Plough (part of Merck) Senju Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju) Senju USA Inc. (subsidiary of Senju) Shire Sirion Therapeutics Sirna Therapeutics Sirnaomics SkinMedica (subsidiary of Allergan) Spark Therapeutics Symphony ViDA Takeda Pharmaceutical Teva The Patent Board ThromboGenics Upjohn (acquired by Pfizer through Pharmacia) Valeant Pharmaceuticals Ventana Medical Systems (acquired by Roche) Versant Ventures Warburg Pincus LLC Warner-Lambert (acquired by Pfizer) Watson Pharmaceuticals Wyeth Pharmaceuticals (part of Pfizer)
List of Other Organizations Mentioned in the Report A*STAR Institute for Infocomm Research (Singapore) American Academy of Ophthalmology (AAO) American Diabetes Association American Society of Retina Specialists (ASRS) Association for Research in Vision and Ophthalmology (ARVO) Council of Europe Emory University European Medicines Agency (EMA) Foundation Fighting Blindness (FFB) (US) Health Canada Institute of Experimental Medicine (Russia) Institute of Ocular Pharmacology, Texas A&M (US) Institute of Ophthalmology, University College London (UK) Intellectual Property Appellate Board (India) International Diabetes Federation Internet Archive Japan Patent Office (JPO) Mayo Clinic Ministry of Health, Labour and Welfare (MHLW) (Japan) Monash University National Eye Institute (NEI) (US) National Health Service (NHS) (UK) National Institute for Health and Care Excellence (NICE) (UK) NHS Scotland Novartis Institutes for BioMedical Research (NIBR) (part of Novartis) Novartis Venture Funds (NVF) (part of Novartis) Ophthalmology External Research Unit (part of Pfizer) Ophthrisi (GSK research unit) Rinat (Pfizer research unit) Texas Emerging Technology Fund Therapeutic Goods Administration (TGA) (Australia) Tokyo University of Science United States Food and Drug Administration (FDA) University of Florida University of Kentucky University of Melbourne University of Michigan US Preventive Services Task Force (USPSTF) US Securities and Exchange Commission (SEC) World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top 30 Ophthalmic Drug Manufacturers 2019-2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
